Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Doxorubicin in Soft Tissue Sarcoma
NCT03056001Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- May 2017
- Primary completion
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in soft tissue sarcoma (STS), sponsored by Wake Forest University Health Sciences. Primary endpoint: Number of Participants With at Least One Severe or Life-Threatening Adverse Event. Started May 2017; status: completed.
02
Drugs
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03056001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056001.